Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Xiu LiuKai OuXiaoting MaLizhen GaoQi WangHaizeng ZhangLin YangPublished in: BMC cancer (2022)
The use of the XELOXIRI regimen with or without a targeted drug was effective, with a manageable toxicity profile in Chinese patients with mCRC.